Background: Psychostimulant treatment may improve simulated driving performance in young adults with attention-deficit/hyperactivity disorder (ADHD). Method: This was a randomized, double-blind, placebo-controlled, crossover study of simulated driving performance with mixed amphetamine salts—extended release (MAS XR) 50 mg/day (Cohort 1) and atomoxetine 80 mg/day (Cohort 2) in young adults with ADHD. Results: Adults aged 19 to 25 years with AD/HD (N = 19) who were administered MAS XR significantly improved overall simulated driving performance versus placebo up to 12 hours after dosing. In contrast, there were no statistically significant differences in simulated-driving-performance scores between atomoxetine and placebo. At endpoint, MAS XR reduced ADHD Rating Scale scores ≥ 30% in 80% of subjects, whereas atomoxetine achieved this level of improvement for 40%. Limitations: Small sample size and use of simulated driving may limit generalizability of the findings. Conclusion: MAS XR in young adults with ADHD yields significant improvements in simulated driving performance and ADHD symptoms. (J. of Att. Dis. 2009; 12(4) 316-329)
American Academy of Pediatrics. (2000). Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics, 105, 1158-1170.
2.
American Psychiatric Association. (2000). Diagnostic and statistical manual for mental disorders-fourth edition text revision (DSM-IV-TR). Washington, DC: Author.
3.
Barkley, R.A. (2002). Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 63(Suppl. 12), 10-15.
4.
Barkley, R.A. (2004). Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatric Clinics of North America, 27, 233-260.
5.
Barkley, R.A., Anderson, D.L., & Kruesi, M. (2007). A pilot study of the effects of atomoxetine on driving performance in adults with ADHD. Journal of Attention Disorders, 10, 306-316.
6.
Barkley, R.A., Guevremont, D.C., Anastopoulos, A.D., DuPaul, G.J., & Shelton, T.L. (1993). Driving-related risks and outcomes of attention-deficit/hyperactivity disorder in adolescents and young adults: A 3- to 5-year follow-up survey . Pediatrics, 92, 212-218.
7.
Barkley, R.A., Murphy, K.R., & Fischer, M. (2007). The science of ADHD in adults: Clinic-referred adults vs. children grown up. New York: Guilford.
8.
Barkley, R.A., Murphy, K.R., & Kwasnik, D. (1996). Motor vehicle driving competencies and risks in teens and young adults with attention-deficit/hyperactivity disorder. Pediatrics, 98(6,Pt.1), 1089-1095.
9.
Barkley, R.A., Murphy, K.R., O'Connell, T., & Connor, D.F. (2005). Effects of two doses of methylphenidate on simulator driving performance in adults with attention-deficit/hyperactivity disorder . Journal of Safety Research, 36, 121-131.
10.
Biederman, J., Faraone, S.V., Monuteaux, M.C., Bober, M., & Cadogen, E. (2004). Gender effects on attention-deficit/ hyperactivity disorder in adults, revisited. Biological Psychiatry, 55, 692-700.
Brown, T.E. (2005). Attention deficit disorder: The unfocused mind in children and adults. New Haven, CT: Yale University Press.
13.
Castellanos, F.X., Sonuga-Barke, E.J., Milham, M.P., & Tannock, R. (2006). Characterizing cognition in ADHD: Beyond executive dysfunction. Trends in Cognitive Science, 10, 117-123.
14.
Cognitive Research Corporation. (2007). Crash Likely Event Rating Scale. St. Petersburg, FL: Author.
15.
Conners, C.K., Erhardt, D., & Sparrow, E.P. (1999). Conners'Adult ADHD Rating Scales (CAARS) technical manual. New York: Multi-Health Systems .
16.
Cox, D.J., Humphrey, J.W., Merkel, R.L., Penberthy, J.K., & Kovatchev, B. (2004). Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. Journal of the American Board of Family Practice , 17, 235-239.
17.
Cox, D.J., Merkel, R.L., Kovatchev, B., & Seward, R. (2000). Effect of stimulant medication on driving performance of young adults with attention-deficit/hyperactivity disorder: A preliminary, double-blind, placebo-controlled trial. Journal of Nervous and Mental Disease, 188, 230-234.
18.
Cox, D.J., Merkel, R.L., Moore, M., Thorndike, F., Muller, C., & Kovatchev, B. (2006). Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics, 118, e704-e710.
19.
Cox, D.J., Merkel, R.L., Penberthy, J.K., Kovatchev, B., & Hankin, C.S. (2004). Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 269-275.
20.
Dulcan, M. (1997). Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 36(10 Suppl.), 85S-121S.
21.
DuPaul, G.J., Power, T., Anastopoulos, A., & Reid, R. (1998). In G. J. DuPaul (Ed.), ADHD rating scale IV: Checklist, norms, and clinical interpretation . New York: Guilford.
22.
Eli Lilly and Company. (2006). Strattera (atomoxetine HCl) prescribing information. Indianapolis, IN: Author.
23.
Faraone, S.V., Biederman, J. (2005). What is the prevalence of adult ADHD? Results of a population screen of 966 adults. Journal of Attention Disorders, 9, 384-391.
24.
Faraone, S.V., Biederman, J., Doyle, A., Murray, K., Petty, C., Adamson, J.J., et al. (2006). Neuropsychological studies of late onset and subthreshold diagnoses of adult attention-deficit/hyperactivity disorder . Biological Psychiatry, 60, 1081-1087.
25.
Fischer, M., Barkley, R.A., Smallish, K., & Fletcher, K. (2007). Hyperactive children as adults: Driving behavior, safe driving abilities, and adverse driving outcomes. Accident Analysis and Prevention, 39, 94-105.
26.
Fried, R., Petty, C.R., Surman, C.B., Reimer, B., Aleardi, M., Martin, J.M., et al. (2006). Characterizing impaired driving in adults with attention-deficit/hyperactivity disorder: A controlled study. Journal of Clinical Psychiatry, 67, 567-574.
27.
Golden, C.J., & Freshwater, S.M. (2002). A manual for the Adult Stroop Color and Word Test. Chicago: Stoelting.
28.
Goodman, D.W., Ginsberg, L.D., Weisler, R.H., Cutler, A.J., & Hodgkins, P. (2005). An interim analysis of the quality of life, effectiveness, safety, and tolerability (QUEST) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrums, 10(12, Suppl. 20), 26-34.
29.
Greenhill, L.L., Pliszka, S., & Dulcan, M.K. for the American Academy of Child and Adolescent Psychiatry. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry, 41(2 Suppl.), 26S-49S.
30.
Guy, W. (1976). 028 Clinical Global Impressions. In ECDEU assessment manual for psychopharmacology (pp. 217-222). Washington, DC: U.S. Department of Health, Education and Welfare, National Institute of Mental Health.
31.
Kempton, S., Vance, A., Maruff, P., Luk, E., Costin, J., & Pantelis, C. (1999). Executive function and attention-deficit/hyperactivity disorder: Stimulant medication and better executive function performance in children. Psychological Medicine, 29, 527-538.
32.
Kessler, R.C., Adler, L., Barkley, R., Biederman, J., Conners, C.K., Demler, O., et al. (2006). The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication . American Journal of Psychiatry, 163, 716-723.
33.
Knouse, L.E., Bagwell, C.L., & Barkley, R.A. (2005). Accuracy of self-evaluation in adults with ADHD: Evidence from a driving study. Journal of Attention Disorders , 8, 221-234.
34.
Murphy, K., & Barkley, R.A. (1996). Attention-deficit/hyperactivity disorder adults: Comorbidities and adaptive impairments. Comprehensive Psychiatry , 37, 393-401.
35.
National Highway Traffic Safety Association (NHTSA).Objective 3, determine the differences in demographic data, test battery results, and performance-based measures between inattentive and attentive drivers (chapter 4). Retrieved August 29, 2007, from http://www.-nrd.nhtsa.dot.gov/departments/nrd-13/810594/pages/4aObjective3.htm
36.
Owen, A.M., Stern, C.E., Look, R.B., Tracey, I., Rosen, B.R., & Petrides, M. (1998). Functional organization of spatial and non-spatial working memory processing within the human lateral frontal cortex. Proceedings of the National Academy of Sciences, USA, pp. 7721-7726.
37.
Pliszka, S., Bernet, W., Bukstein, O., et al., and the AACAP Work Group on Quality Issues. (2007). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 894-921.
38.
Reitan, R.M., & Wolfson, D. (1993). The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation (2nd ed.). South Tucson, AZ: Neuropsychology Press.
39.
Rowland, A.S., Lesesne, C.A., & Abramowitz, A.J. (2002). The epidemiology of attention-deficit/hyperactivity disorder (ADHD): A public health view. Mental Retardation and Developmental Disabilities Research Reviews, 8, 162-170.
40.
SAS Institute. (1997). SAS/STAT software: Changes and enhancements through release 6.12. Cary, NC: SAS Institute.
41.
U.S. Census Bureau. (2003). Census 2000 Summary File 4. Retrieved August 16, 2004, from http://factfinder.census.gov
42.
Virani, A. (2005). Perspectives in psychopharmacology: Spotlight on atomoxetine. The Canadian Child and Adolescent Psychiatry Review, 14, 96-98.
43.
Wechsler, D. (1999). Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: The Psychological Corporation.
44.
Wilens, T.C., & Dodson, W. (2004). A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. Journal of Clinical Psychiatry, 65, 1301-1313.
